
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Blockbuster drugs turn out to be risky business, while contamination problems shut down flu vaccine production.
almost 22 years ago
In the Spotlight-December 2004almost 22 years ago
December 2004almost 22 years ago
Robust CRO Market Is Driving New Merger and Acquisition Activityalmost 22 years ago
The Seventh Annual International Employment Surveyalmost 22 years ago
Pharmaco-Fakery




